Ovid Therapeutics Announces Appointment of Highly-Ranked Biotechnology Research Analyst Dr. Yaron Werber as Chief Financial Officer
New York, NY – June 4, 2015 – (Business Wire) – Ovid Therapeutics Inc. (Ovid), a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, today announced the appointment of Yaron Werber, M.D., MBA, to the position of Chief Financial Officer, replacing interim CFO Mark Feldberg, who will continue in his role at TradeLink. With nearly 15 years of experience as a highly-ranked biotechnology research analyst at marquee Wall Street firms, Dr. Werber brings a distinguished track record of success to Ovid. He will join effective June 22, 2015, and will report to Dr. Jeremy Levin, Chief Executive Officer and Chairman of Ovid. Dr. Werber will be responsible for all financial planning and reporting, will head investor and public relations, and will support Ovid’s business development initiatives.
“Yaron brings an extensive financial background as well as a wealth of experience and relationships that are ideally suited to Ovid,” commented Dr. Levin. “The Company is on a rapid trajectory, as we move our lead programs into the clinic, further build our team, and complete additional key transactions. Yaron’s critical insights and keen understanding of the capital markets and investors will contribute greatly to the progress of Ovid. We welcome Yaron, and are also grateful to Mark for his work during Ovid’s formational period.”
“I am extremely impressed with the progress that Ovid has made over the past year, especially as it gears up to initiate Phase 2 trials for OV101 in 2016 for the treatment of Angelman Syndrome and Fragile X Syndrome,” Dr. Werber stated. “Ovid’s strategy is to focus on orphan diseases of the brain based on compelling advances in the science of receptor signaling, allowing the Company to build a deep and novel pipeline in diseases with substantial unmet needs. This pipeline, along with the team’s proven operational, product development and business development expertise, provide Ovid with a strong foundation to continue to grow and advance the Company. I am very excited to join the Company and help build Ovid into a leading neurology company that brings important medicines to patients.”
Prior to joining Ovid, Dr. Werber was a Managing Director at Citi Research, and the Head of the Healthcare and Biotech Equity Research teams. For the past several years, he has been highly ranked by the Institutional Investor Magazine survey, and has been ranked among the top five analysts in the biotech sector by the “Best on the Street Survey” of the Wall Street Journal. During his 11-year tenure at Citi, Dr. Werber and his team have conducted in-depth analysis of more than 80 life science companies at all stages of development, ranging from successful profitable companies to recently public and privately held companies. Previously, Dr. Werber was Senior Biotech Analyst and Vice President at SG Cowen Securities. He began his career in academic research, was director of business development at NotifyMD, a privately held e-health company, and also consulted to leading healthcare organizations. Dr. Werber received a BS degree in Biology from Tufts University and a combined MD/MBA degree from Tufts University School of Medicine.
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a privately-held, New York based, biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain and few, if any, treatment options – patients who currently have no hope of cure or improvement. Ovid focuses on patients and their needs. Using the significant operational, product development and business development experience of its management team, Ovid aims to become a leading neurology company, with multiple products and a rich pipeline, coupled with compelling research and development.
For more information on Ovid, please visit http://ovidrx.com.
Burns McClellan, on behalf of Ovid Therapeutics
Justin Jackson, 212-213-0006, ext. 327